Drugs & Targets PolyPid announces collaboration with ImmunoGenesis in solid tumors December 13, 2024Vol.50 No.46
Drugs & Targets Dewpoint Therapeutics and ConcertAI form drug development partnership December 13, 2024Vol.50 No.46
Conversation with The Cancer Letter Brian Druker steps down as CEO of OHSU Knight Cancer Center December 06, 2024Vol.50 No.45By Paul Goldberg
NCI NCI paylines to drop to 9th percentile amid CRs and uncertainty December 06, 2024Vol.50 No.45By Jacquelyn Cobb
News Analysis What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted researchFormer FDA Commissioner Scott Gottlieb expresses “deep concerns” December 06, 2024Vol.50 No.45By Claire Marie Porter
In Brief Andrew Evens named editor-in-chief of the British Journal of Haematology; Phillip Scheinberg named editor-in-chief of eJHaem December 06, 2024Vol.50 No.45
In Brief President’s Cancer Panel urges enhanced patient navigation through technology to improve health equity December 06, 2024Vol.50 No.45
In Brief Break Through Cancer launches the PoweRD 2 Cure ALK+ Lung Cancer TeamLab December 06, 2024Vol.50 No.45
